Lindahl advises Corline Biomedical AB on directed share issue
Lindahl is acting as legal adviser to Corline Biomedical AB (publ) in connection with a directed share issue amounting to approximately SEK 23 million.
Through the share issue, Corline Biomedical will receive approximately SEK 23 million before deduction of issue costs. In addition, the company strengthens its shareholder base with a long-term and international investor, Eiffel Investment Group, to which the issue is directed.
Corline Biomedical develops and sells medical technology solutions. The company's shares are listed on Nasdaq First North Growth Market.
Lindahl's team consists of Mattias Prage and Olle Swärd Brattström.
Do you want to know more? Contact:
Mattias Prage
Partner | AdvokatOlle Swärd Brattström
AssociateCarousel items
-
Cases and transactions
10/2/2026
Lindahl advises NordAmps AB (publ) on listing on Nasdaq First North Growth Market
Lindahl has acted as legal counsel to NordAmps AB (publ) in connection with the company’s listing on Nasdaq First North Growth Market.
-
Knowledge
9/28/2026
The Supreme Administrative Court settles the matter – an extension can fall within the lease exemption
The Supreme Administrative Court clarifies that the lease exemption under the Swedish Public Procurement Act can apply even when a lease agreement includes an extension constituting a works contract, provided the tenancy is the contract's main sub...
-
News articles
9/4/2026
Mikael Wärnsby represents Sweden at international conference on new nuclear power
Mikael Wärnsby represented Sweden at EFELA’s international conference on licensing and regulatory frameworks for new nuclear power in Europe.
-
Portraits
7/3/2026
Jesper on business-oriented legal advice in energy: "It is not enough for the advice to be correct"
Lindahl's energy team is recognised in Legal 500 for combining deep regulatory expertise with broad commercial legal experience – find out how they support clients in a rapidly evolving sector.
-
Read more news and insights?
